{"ModuleTitle": "Company Description", "CompanyName": "Cyclacel Pharmaceuticals, Inc.", "Symbol": "CYCC", "Address": "200 CONNELL DRIVE SUITE 1500, BERKELEY HEIGHTS, New Jersey, 07922, United States of America", "Phone": "908-517-7330", "Industry": "Major Pharmaceuticals", "Sector": "Health Care", "Region": "North America", "CompanyDescription": "The following Business Section contains forward-looking statements. Our actual\r\nresults could differ materially from those anticipated in these forward-looking\r\nstatements as a result of certain risks, uncertainties and other factors\r\nincluding the risk factors set forth in Part I, Item 1A of this Annual Report on\r\nForm 10\u00adK. In this report, \"Cyclacel,\" the \"Company,\" \"we,\" \"us,\" and \"our\"\r\nrefer to Cyclacel Pharmaceuticals, Inc.\r\n\r\nGeneral\r\n\r\nCyclacel is a clinical-stage biopharmaceutical company using its expertise in\r\ncell cycle, transcriptional regulation and DNA damage response biology in cancer\r\ncells to develop innovative, targeted medicines for cancer and other serious\r\ndiseases. Cyclacel is a pioneer company in the field of cancer cell cycle\r\nbiology with a vision to improve patient healthcare by translating insights in\r\ncancer biology into medicines.&nbsp;&nbsp;... <a href=\"http://secfilings.nasdaq.com/filingFrameset.asp?FileName=0000950136%2D06%2D004797%2Etxt&FilePath=%5C2006%5C06%5C12%5C&CoName=CYCLACEL+PHARMACEUTICALS%2C+INC%2E&FormType=S%2D3&RcvdDate=6%2F12%2F2006&pdf=\" target=\"_blank\">More</a> ...&nbsp;&nbsp;\r\n", "KeyExecutives": [{"name": "Judy Chiao", "title": "VP-Clinical Development & Regulatory Affairs"}, {"name": "Paul McBarron", "title": "Chief Operating, Financial Officer & Secretary"}, {"name": "Spiro Rombotis", "title": "President, Chief Executive Officer & Director"}], "Number_of_employees": [], "Subsidiaries": ["NO INFO"]}